RX:CA:CDX-BioSyent Inc (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic | TSX Venture Exchange

Last Closing

USD 9

Change

0.00 (0.00)%

Market Cap

USD 0.11B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Biosyent Inc is a life science company engaged in marketing of pharmaceutical products & manufacturing & marketing of non-chemical bio & health-friendly insecticides. It acquires or license products & commercializes technology to health & public safety.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZYUS:CA ZYUS Life Sciences Corporation

-0.01 (-0.95%)

USD 0.08B
LOVE:CA Cannara Biotech Inc

-0.01 (-1.37%)

USD 0.06B
SBBC:CA Simply Better Brands Corp

N/A

USD 0.06B
LSL:CA LSL Pharma Group Inc.

+0.01 (+1.05%)

USD 0.06B
DB:CA Decibel Cannabis Company Inc

N/A

USD 0.03B
ROMJ:CA Rubicon Organics Inc

-0.02 (-4.08%)

USD 0.03B
PCLO:CA Pharmacielo Ltd

N/A

USD 0.03B
ELXR:CA Elixxer Ltd

N/A

USD 0.01B
MPH:CA Medicure Inc

-0.01 (-0.93%)

USD 0.01B
VM:CA Voyageur Pharmaceuticals Ltd

N/A

USD 0.01B

ETFs Containing RX:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.39% 67% D+ 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.39% 67% D+ 51% F
Trailing 12 Months  
Capital Gain 17.65% 95% A 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.65% 95% A 77% C+
Trailing 5 Years  
Capital Gain 10.43% 90% A- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.43% 90% A- 65% D
Average Annual (5 Year Horizon)  
Capital Gain 12.14% 85% B 64% D
Dividend Return 12.14% 85% B 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.03% 95% A 80% B-
Risk Adjusted Return 44.90% 100% F 89% A-
Market Capitalization 0.11B 100% F 92% A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.